glp 1 and graves disease Can a patient with safely start a GLP‑1 receptor agonist for diabetes or weight loss, what monitoring is recommended? The expanding role of GLP-1
Description
Glucagon-like peptide-1 (GLP-1) agonists are widely known for their role in managing type 2 diabetes and promoting weight loss
Across studies, fat mass decline predominated, whereas reductions in lean body mass were modest
For example, semaglutide and empagliflozin showed no significant difference in 3-point MACE (HR 1.05
- Sodium
US | GL-1 8--1 & ( , 7 ) , , , , , ,
